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Abstract
Background: To determine the prevalence, distribution, concordance and associations of chronic kidney disease
(CKD) determined by five glomerular filtration rate (GFR) formulae in urban black residents of Cape Town.
Methods: Data collection in this cross-sectional study included interviews, clinical measurements and biochemical
analyses, including serum creatinine and cystatin C levels. GFR was based on the CKD Epidemiology Collaboration
(CKD-EPI) equations (CKD-EPI creatinine (CKD-EPIcr), CKD-EPI cystatin C (CKD-EPIcys), CKD-EPI creatinine-cystatins
(CKD-EPIcr-cys)), Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault formula (CGF). GFR < 60 mL/min/
1.73 m2 defined CKD.
Results: Among 392 men and 700 women, mean GFR, was between 114.0 (CKD-EPIcr) and 135.4 mL/min/1.73 m2
(CGF) in men, and between 107.5 (CKD-EPIcr-cys) and 173.4 mL/min/1.73 m2 (CGF) in women. CKD prevalence
ranged from 2.3% (CKD-EPIcr and MDRD) to 5.1% (CKD-EPIcys) in men and 1.6% (CGF) to 6.7% (CKD-EPIcr-cys) in
women. The kappa statistic was high between CKD-EPIcr and MDRD (0.934), and CKD-EPIcys and CKD-EPIcr-cys
(0.815), but fair-to-moderate between the other eqs. (0.353–0.565). In the basic regressions, older age and body
mass index ≥30 kg/m2, but not gender, were significantly associated with CKD-EPIcr-defined CKD. In the presence
of these three variables, hypertension, heart rate ≥ 90 beats/minute, diabetes and low-density lipoprotein
cholesterol were significant predictors of prevalent CKD.
Conclusions: Varying CKD prevalence estimates, because of different GFR equations used, underscores the need to
improve accuracy of CKD diagnoses. Furthermore, screening for CKD should be incorporated into the routine
assessment of high-risk patients such as those with hypertension or diabetes.
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Background
There has been a global increase in chronic kidney dis-
ease (CKD) over the last 2–3 decades [1]; the estimated
prevalence is > 10% [2]. Contributing to the rise in CKD
is the worldwide increase in prevalence of hypertension,
diabetes, obesity and the metabolic syndrome. While
these conditions are risk factors for cardiovascular dis-
ease (CVD), the presence of CKD further raises the risk
and worsens prognosis; CKD is recognised as an import-
ant and independent risk factor for CVD [2].
CKD is a serious, debilitating and potentially expensive
disease to treat with complications placing a huge bur-
den on healthcare resources [1]. In the later stages of
CKD, where there is progression to end-stage renal dis-
ease (ESRD), the focus is on management of complica-
tions and preparation and implementation of renal
replacement therapy [3]. ESRD is serious and its man-
agement is costly and unaffordable for many countries.
Only a few wealthy countries and individuals with access
to private health insurance can meet the demands im-
posed by the late stages of CKD [1]. Notably, these op-
tions are frequently not available to the poor due to high
costs nor in developing nations with limited resources
and where renal transplantation may not even be avail-
able [3]. This leads almost inevitably to premature mor-
tality and impacts hugely on families, both emotionally
and economically with loss of income from breadwin-
ners who are usually of working-age.
Thus, there is an urgent need to shift attention in the
management of CKD from ESRD to prevention, and
early detection and retarding progression to ESRD [1, 3].
Since the earlier stages of CKD may be asymptomatic,
screening is necessary for early detection and timely in-
terventions to prevent, delay or reverse subsequent dis-
ease progression [3, 4].
To address the burden of CKD, there needs to be an
increased awareness and understanding of the problem
to encourage regular screening. This can only be
achieved by assessing and highlighting the burden of the
problem through epidemiological studies of the inci-
dence, prevalence and determinants of CKD [1, 5]. Such
data can inform the appropriate allocation of resources
to prevent CKD and encourage its early detection to
pre-empt progression to ESRD. This is particularly rele-
vant in resource-limited setting such as South Africa.
However, in South Africa, there is a dearth of such data
with only a few studies reporting on the burden of CKD
in general populations [6–8].
Furthermore, there are several formulae to estimate
glomerular filtration rate (GFR), the accepted best overall
index of renal function [9]. The GFR estimators com-
monly used are the Cockcroft-Gault formula (CGF) [10],
the Modification of Diet in Renal Disease (MDRD) [11]
and the recently developed CKD Epidemiology
Collaboration (CKD-EPI) equations [9, 12]. These formu-
lae use serum creatinine concentrations, as advocated for
screening [7]; however, additional CKD-EPI equations in-
clude cystatin C. Cystatin C has been evaluated as an al-
ternative filtration marker to serum creatinine and has
been reported to be a better marker than creatinine [12];
estimated GFR (eGFR) based on cystatin C equations may
be used as a confirmatory test for renal disease [13]. Few
studies in Africa have estimated and compared GFR and
determined the prevalence of CKD by these equations
simultaneously.
The aim of this study was to determine the prevalence,
distribution, concordance and cardiometabolic associa-
tions of CKD determined by five eGFR formulae in
urban black residents of Cape Town. The eGFR equa-
tions used include the CGF [10], the more popular
MDRD [11, 14], the creatinine-based CKD-EPI (CKD-
EPIcr) equation [9] recommended for the initial assess-
ment of GFR and the two cystatin C-based CKD-EPI
equations [12]. The MDRD and CKD-EPI equations
have not been adjusted for ethnicity as recommended
for African Americans because this has been reported to
overestimate kidney function in black South Africans
[15]. Similarly, these ethnicity coefficients did not per-
form well in other Sub-Saharan African populations
[16], African Europeans and indigenous Australians [17].
GFR was best estimated when the ethnicity factor was
disregarded because the performance of the CKD-EPI
and MDRD GFR estimates did not improve with these
ethnic adjustments [16, 17].
Methods
Study population, sampling procedure and data
collection
This cross-sectional study was conducted in men and
women residing in the predominantly black townships
of Langa, Guguletu, Crossroads, Nyanga and Khayalitsha
in Cape Town. Based on an estimated diabetes preva-
lence of 8% with a precision of 1.5% two-sided with 95%
confidence, a sample size of 1000 was planned. Partici-
pants were randomly selected in 2008/09 using a 3-stage
cluster sampling procedure, which has previously been
described in detail [18]. Aerial maps of each township
were used to randomly select residential blocks within
the main strata followed by selection of individuals from
households using quotas. Quotas, calculated using the
most recent census, were pre-specified by age and gen-
der categories. Sampling across age groups was dispro-
portionate with older age groups over-sampled to ensure
at least 50 men and women in each gender category.
Participants who were unable to give consent, bedridden,
pregnant or lactating, residents of Cape Town for less
than 3 months, on antiretrovirals or tuberculosis
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treatment or had received cancer treatment within the
previous year were ineligible for this study.
Trained fieldworkers conducted the data collection
which comprised administered questionnaires, clinical
assessments and biochemical analyses. This was per-
formed in accordance with the relevant guidelines
and regulations. Fieldworkers administered structured
questionnaires to obtain socio-demographic informa-
tion, self-reported medical history, and data on to-
bacco (WHO STEPwise surveillance questionnaire)
[19] and alcohol use (CAGE set of four questions)
[20]. Assets that defined wealth were recorded and in-
cluded ownership of consumer items (durable goods),
access to electricity, and the source of drinking water
and toilet facilities.
Clinical assessments comprised anthropometric and
blood pressure (BP) measurements. Anthropometric
data included height, weight, and waist and hip cir-
cumferences and were measured using standardised
techniques [21]. Weight was measured to the nearest
0.1 kg using a calibrated scale with the participants
barefoot and in light clothing while a stadiometer
measured height to the nearest 0.1 cm. Waist and hip
circumferences were measured to the nearest 0.1 cm
with a flexible tape measure. The tape measure was
held parallel to the floor while the waist circumfer-
ence was measured approximately 2 cm or two finger
spacings above the umbilicus. Hip circumference was
measured at the maximum posterior protuberance of
the buttocks with participants standing upright and
their feet together.
After the participant had been seated for 5 min, three
BP measurements were taken at two-minute intervals
with an Omron BP monitor using an appropriately sized
cuff. The average of the second and third BP measure-
ments was used for analysis.
Blood samples, for glucose and lipid estimations, were
drawn following a10-hour overnight fast. A standard oral
glucose tolerance test with 75 g of anhydrous glucose
dissolved in 250 ml of water was thereafter administered,
and blood samples drawn 120min later [22]. Blood sam-
ples were kept on ice and transported to the laboratory
within 6 h to be centrifuged, aliquoted and stored at −
80° until the assays were performed.
Additional blood specimens were stored at − 80 de-
grees Celsius and analysed in 2018/2019. The latter bio-
chemical analyses included serum creatinine and
cystatin C levels, which were used to determine eGFR.
Cystatin C was measured on the Roche 502 platform by
a particle enhanced immunoassay which has been stan-
dardised against ERM-DA471/IFCC reference material.
Serum creatinine was measured by Jaffe kinetic method
which is IDMS traceable.
Definitions
CKD was determined using the CKD-EPIcr eq. (2009)
[9], the CKD-EPI cystatin C (CKD-EPIcys) and creatin-
ine–cystatin C (CKD-EPIcr-cys) eqs. (2012) [12], the
MDRD (1999) [11] and the CGF (1976) [10]. These
equations are complex formulae that include age and
gender (in all the above equations) or body mass (CGF
only) in various computations together with serum cre-
atinine or serum cystatin C in specific equations. CKD
was defined as eGFR of < 60 mL/min/1.73 m2. However,
this threshold does not distinguish kidney disease from
kidney aging and may therefore not be applicable for all
ages [23]. Consequently, CKD cut-points were further
adjusted for age-specific thresholds as follows: < 40 years:
< 75 ml/min per 1.73 m2, 40–65 years: < 60 ml/min per
1.73 m2, and > 65 years: < 45 ml/min per 1.73 m2.
Problematic alcohol use was deemed present if ≥2 of
the CAGE set of four questions were answered affirma-
tively [20]. Smoking ≥1cigarette/day categorised partici-
pants who smoked daily. Based on the assets that
defined wealth, a principal component analysis of the
pooled data was used to develop an asset index [24].
Categories of relative wealth were created using tertiles;
the lowest tertile represents the poorest participants.
Body mass index (BMI) was calculated as weight in ki-
lograms divided by height in metres squared (kg/m2)
and obesity defined as BMI ≥30 kg/m2 [25]. Central
obesity was computed as waist circumference > 94 cm in
men and > 80 cm in women, waist-to-hip ratio as ≥0.9 in
men and ≥ 0.85 in women [26] and waist-to-height ratio
as > 0.5 [27]. Hypertension was defined as BP ≥140/90
mmHg or the use of antihypertensive agents [28]. Rest-
ing heart rate of ≥90 beats per minute was categorised
as high.
Diabetes was diagnosed using the 1998 WHO criteria
of fasting plasma glucose ≥7.0 mmol/l and/or 2-h post
glucose load ≥11.1 mmol/l [22], and included partici-
pants with known diabetes. Dyslipidaemia was defined
as follows [29]: total cholesterol > 5 mmol/l, triglycerides
> 1.5 mmol/l, high-density lipoprotein cholesterol (HDL-
C) < 1.2 mmol/l and low-density lipoprotein cholesterol
(LDL-C) > 3.0 mmol/l calculated using the Friedewald
equation [30] or taking anti-lipid agents. Metabolic syn-
drome was defined according to the Joint Interim State-
ment criteria as the presence of any three abnormal
findings out of five components [31].
Statistical analyses
Data analyses were conducted using STATA 15. Univariable
analyses (sociodemographic and CVD risk characteristics)
are presented as crude mean values and standard deviations
for continuous data, and as crude percentages for categorical
data. The agreements between the kidney function
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estimators were determined on a continuous scale using the
Pearson correlation tests, and differences between the correl-
ation coefficients were tested. Cohen’s kappa statistic was
used to test the agreement of CKD between the various
formulae.
Logistic regressions analyses were used to investigate
the association of cardiometabolic risk profile with preva-
lent CKD in age, gender and BMI ≥30 kg/m2 adjusted
models. Thereafter, each cardiometabolic variable was
modelled independently. The data are presented as odds
ratios (OR) and 95% confidence intervals (CI). A p-value
< 0.05 characterised statistically significant findings.
Ethics approval was obtained from the South African
Medical Research Council’s Human Research Ethics
Committee (EC026–9/2016) and the University of Cape
Town’s Research and Ethics Committee (224/2006). All
participants signed informed consent.
Results
Of the 1116 participants examined in this study, 24 were
excluded because they did not have creatinine and cysta-
tin C results to determine eGFR. This was mainly be-
cause of insufficient stored blood samples. The final
study sample included 1092 participants > 21 years of
age and comprised 392 men and 700 women.
The mean eGFR was between 114mL/min/1.73m2
(CKD-EPIcr) and 135mL/min/1.73m2 (CGF) in men, and
108mL/min/1.73m2 (CKD-EPIcr-cys) and 173mL/min/
1.73m2 (CGF) in women (Fig. 1). Compared with women,
mean eGFR in men was significantly higher by the CKD-
Fig. 1 Distribution of mean estimated glomerular filtration rate (eGFR) presented by five formulae in men and women: three CKD-EPI equations,
Cockcroft-Gault and MDRD formulae
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EPI formulae and lower by CGF (both p < 0.05); there was
no significant difference by MDRD. By age category, mean
eGFR generally decreased significantly with older age in
both men and women (p < 0.001).
The correlations between different estimates of GFR
were positive and significant, and there were no signifi-
cant differences between any two coefficients. The high-
est correlation coefficients between the eGFR equations
were for CKD-EPIcys and CKD-EPIcr-cys (total sample:
0.994, men: 0.996, women: 0.995), (Table 1). eGFR by
the cystatin C equations correlated only modestly with
CKD-EPIcr.
The CKD-EPIcr and MDRD equations were strongly
correlated in the total sample (0.814), men (0.863) and
women (0.790). MDRD and CGF were also well corre-
lated (total sample: 0.779, men: 0.839, women: 0.817).
Table 1 Correlation coefficients between the five estimated glomerular filtration rate formulae in urban black men and women
CKD-EPI creatinine CKD-EPI cystatin C CKD-EPIcr-cys Cockcroft-Gault MDRD
Total
CKD-EPI creatinine 1 0.460 0.453 0.681 0.814
CKD-EPI cystatin C 0.460 1 0.994 0.341 0.473
CKD-EPIcr-cys 0.453 0.994 1 0.335 0.477
Cockcroft-Gault 0.681 0.341 0.335 1 0.779
MDRD 0.814 0.473 0.477 0.779 1
Men
CKD-EPI creatinine 1 0.368 0.366 0.796 0.863
CKD-EPI cystatin C 0.368 1 0.996 0.407 0.443
CKD-EPIcr-cys 0.366 0.996 1 0.403 0.440
Cockcroft-Gault 0.796 0.407 0.403 1 0.839
MDRD 0.863 0.443 0.440 0.839 1
Women
CKD-EPI creatinine 1 0.525 0.510 0.702 0.790
CKD-EPI cystatin C 0.525 1 0.995 0.403 0.496
CKD-EPIcr-cys 0.510 0.995 1 0.404 0.502
Cockcroft-Gault 0.702 0.403 0.404 1 0.817
MDRD 0.790 0.496 0.502 0.817 1
CKD-EPIcr-cys CKD-EPI creatinine-cystatin C, MDRD Modification of Diet in Renal Disease
Fig. 2 Prevalence (%) of chronic kidney disease (CKD) by three CKD-EPI, Cockcroft-Gault and MDRD formulae in men and women
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By the various equations, the prevalence of CKD
ranged from 2.0% (CGF) to 5.9% (CKD-EPIcr-cys) in the
total sample, 2.3% (CKD-EPIcr and MDRD) to 5.1%
(CKD-EPIcys) in men and 1.6% (CGF) to 6.7% (CKD-
EPIcr-cys) in women (Fig. 2). There was no significant
difference in the prevalence of CKD between men and
women except by MDRD (p = 0.046).
The overall CKD prevalence by age-specific thresholds
ranged from 1.7% (CGF) to 5.9% (CKD-EPIcr-cys)
(Fig. 3). By age groups, CKD prevalence was as follows:
< 40 years old:1.0% (CGF) to 4.7% (MDRD), 40–65 years
old: 1.8% (CGF) to 6.8% (CKD-EPIcr-cys), and > 65 years
old: 4.6% (CGF) to 9.2% (CKD-EPIcys and CKD-EPIcr-
cys). CKD prevalence by age-specific thresholds
Fig. 3 Prevalence (%) of chronic kidney disease (CKD) by three CKD-EPI, Cockcroft-Gault and MDRD formulae using age-specific thresholds
Table 2 Cross classification of participants with chronic kidney disease by the various formulae and the kappa statistic for each
comparison
CKD-EPI cystatin C CKD-EPIcr-cys Cockcroft-Gault MDRD
yes no yes no yes no yes no
CKD-EPI creatinine
yes 21 16 22 15 17 20 37 0
no 29 1026 42 1013 5 1050 5 1050
Kappa 0.462 0.410 0.565 0.934
CKD-EPI cystatin C
yes 47 3 16 34 21 29
no 17 1025 6 1036 21 1021
Kappa 0.815 0.429 0.433
CKD-EPIcr-cys
yes 16 48 23 41






Number of participants with chronic kidney disease (CKD): CKD-EPI creatinine: n = 37; CKD-EPI cystatin C: n = 50; CKD-EPI creatinine-cystatin C (CKD-EPIcr-cys): n =
64; Cockcroft-Gault: n = 22; Modification of Diet in Renal Disease (MDRD): n = 42
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increased with age but was significantly different only
for CKD-EPIcr (p = 0.043) and for CKD-EPIcys (p =
0.027).
The kappa statistic for CKD was high between CKD-
EPIcr and MDRD (0.934), and between CKD-EPIcys and
CKD-EPIcr-cys (0.815), while the lowest kappa statistic
was between CKD-EPIcr-cys and CGF (0.353) (Table 2).
The kappa statistics for the other comparisons were
moderate in agreement (0.410–0.565).
The prevalence of participants who had eGFR of 60–
90mL/min/1.73 m2 by the creatinine-defined formulae
but CKD on CKD-EPIcys and CKD-EPIcr-cys is as fol-
lows: CKD-EPIcr (n = 142): 12.7 and 16.2%, CGF (n =
120): 13.3 and 16.7%, and MDRD (n = 221): 9.1 and
11.3%, respectively (Supplementary Figure 1).
The prevalence of CKD by the CKD-EPIcr was signifi-
cantly higher in participants who were older, pensioners,
lived in formal housing and had a history of heart attack
or stroke (Supplementary Table 1). Participants with
compared to without cardiometabolic diseases generally
had significantly higher prevalence of CKD across the
eGFR formulae (Supplementary Figure 2). However, the
CKD prevalence was not significantly higher for LDL-C
determined by CKD-EPIcys and CGF, and for metabolic
syndrome determined by CGF in participants with com-
pared to without these conditions.
Measures of adiposity (except for waist-to-hip ratio),
systolic and diastolic BPs and hypertension, fasting and
2-h glucose and diabetes, and metabolic syndrome were
significantly higher in participants with compared to
without CKD (Supplementary Table 2). Mean lipid
levels and dyslipidaemia, except for mean HDL-C, and
prevalence of low HDL-C and raised triglycerides, were
significantly higher in participants with compared to
without CKD.
In the age, gender and BMI adjusted regression model
(basic model), ages 55–64 years and ≥ 65 years and BMI
≥30 kg/m2 were significantly associated with CKD-
EPIcr-defined CKD (Table 3). When the cardiometabolic
variables were entered separately and individually in the
above model, hypertension (OR: 2.57, 95% CI: 1.01–
6.50), heart rate ≥ 90 beats/min (OR: 3.98, 95%CI: 1.56–
10.14), diabetes (OR: 2.09, 95% CI: 1.01–4.30) and in-
creasing LDL-C (OR: 1.44, 95% CI: 1.02–2.02) were sig-
nificant. The model with metabolic syndrome, adjusted
for age and gender but not BMI ≥30 kg/m2, was also sig-
nificant (OR: 2.70, 95% CI: 1.20–6.06).
In the basic models for CKD determined by the other
eGFR equations, older age was generally significant while
BMI ≥30 kg/m2 was significant for the CKD-EPI equa-
tions (Table 3). Cardiometabolic variables were not sig-
nificant when entered separately and individually in
Table 3 Multiple logistic regression models (odds ratios and 95% confidence intervals) for the associations with chronic kidney
disease (CKD) determined by the CKD-EPI, Cockcroft-Gault and MDRD formulae
CKD-EPI creatinine CKD-EPI cystatin C CKD-EPI creatinine-cystatin C Cockcroft-Gault MDRD
Age in years: < 34 1.00 1.00 1.00 1.00 1.00
35–44 0.89 (0.15–5.40) 7.99 (0.95–66.87) 1.66 (0.50–5.50) 2.74 (0.25–30.26) 1.38 (0.34–5.60)
45–54 3.76 (1.00–14.17) 12.92 (1.64–102.02) 3.50 (1.22–10.01) 6.20 (0.68–56.27) 3.65 (1.14–11.71)
55–64 10.15 (2.80–36.82) 29.05 (3.73–226.48) 9.83 (3.56–27.17) 10.25 (1.13–92.96) 7.90 (2.49–25.11)
≥ 65 14.95 (4.03–55.52) 98.09 (12.92–745.01) 22.20 (8.05–61.24) 53.55 (6.74–425.36) 11.81 (3.62–38.49)
Gender: female 1.13 (0.47–2.73) 0.53 (0.26–1.09) 1.23 (0.63–2.41) 0.61 (0.23–1.65) 1.56 (0.66–3.64)
BMI ≥30 kg/m2 2.81 (1.21–6.55) 2.60 (1.26–5.38) 1.98 (1.06–3.69) 0.81 (0.29–2.24) 2.04 (0.95–4.35)
Hypertension 2.57 (1.01–6.50) 1.73 (0.83–3.58) 1.70 (0.89–3.24) 3.09 (0.95–10.04) 2.61 (1.13–6.04)
Heart rate≥ 90 beats/min 3.98 (1.56–10.14) 1.96 (0.70–5.53) 1.54 (0.60–3.95) 1.91 (0.41–8.98) 3.14 (1.27–7.74)
Diabetes 2.09(1.01–4.30) 1.30 (0.66–2.57) 1.02 (0.54–1.93) 1.81 (0.69–4.73) 1.82 (0.91–3.66)
Increasing TC 1.15 (0.86–1.54) 1.06 (0.81–1.38) 1.04 (0.82–1.31) 1.14 (0.78–1.65) 1.15 (0.87–1.50)
Increasing HDL-C 0.45 (0.15–1.35) 0.79 (0.36–1.73) 0.65 (0.31–1.38) 0.60 (0.19–1.88) 0.54 (0.21–1.42)
Increasing triglycerides 1.23(0.99–1.54) 1.17 (0.94–1.45) 1.10 (0.87–1.40) 1.21 (0.96–1.54) 1.20 (0.98–1.47)
Increasing LDL-C 1.44(1.02–2.02) 1.18 (0.87–1.62) 1.18 (0.90–1.56) 1.52 (0.98–2.33) 1.39 (1.02–1.91)
Increasing HDL-C: TC ratio 0.96 (0.90–1.01) 1.01 (0.99–1.04) 1.00 (0.98–1.03) 0.98 (0.93–1.03) 0.96 (0.91–1.01)
Metabolic syndrome 2.70 (1.20–6.06) 1.16 (0.61–2.22) 1.15 (0.65–2.06) 1.38 (0.54–3.57) 2.99 (1.39–6.46)
Significant values (p < 0.05) are in bold. MDRD: Modification of Diet in Renal Disease, BMI: body mass index; TC: total cholesterol; HDL-C: high-density lipoprotein
cholesterol; LDL-C: low-density lipoprotein cholesterol. The models with metabolic syndrome were adjusted for age and gender but not BMI ≥30 kg/m2. When the
cardiometabolic variables were entered separately and individually in the basic model (age, gender and body mass index) for CKD determined by the CDK-EPI
creatinine formula, there was no change in the direction or significance of the other variables except for the model with heart rate where age 45–54 years was
now significant. For CKD determined by CKD-EPI cystatin C, CKD-EPI creatinine/cystatin C and MDRD formula, age 45–54 years and BMI ≥30 kg/m2 were no longer
significant in some models when the cardiometabolic variables were entered separately and individually in the basic models. Age 55–64 years was not significant
in the Cockcroft-Gault models with hypertension, LDL-C or metabolic syndrome
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these models except for MDRD derived CKD. Hyperten-
sion, raised heart rate, increasing LDL-C and metabolic
syndrome were significantly associated with MDRD de-
rived CKD.
Discussion
To our knowledge, this study is among the first to exam-
ine and compare eGFR and the prevalence of CKD de-
rived from multiple formulae, including the cystatin C-
based equations, across age and gender categories in an
urban black community in South Africa and Sub-
Saharan Africa in general. The prevalence of CKD, de-
rived from the three CKD-EPI equations, CGF and
MDRD, ranged from 2% (CGF) to 6% (CKD-EPIcr-cys)
in the total sample. This was similar to a recent system-
atic review and meta-analysis of CKD prevalence studies
from Africa (4.6%) [32], but slightly lower than the
MDRD-defined CKD prevalence of 6.3% in black South
Africans from Soweto, Johannesburg [7]. Compared with
this study, CKD prevalence in Cape Town was also
higher in a mixed ancestry population (CKD-EPIcr:
17.3%; MDRD: 23.9%) [6] and among teachers (MDRD
or proteinuria: 10.4%) [8]. The higher CKD prevalence
in the latter study may be attributed to the inclusion of
proteinuria in the diagnosis, and in the former to the
mean older age (53 years) and higher prevalence of dia-
betes (26.4%) compared with this sample; hypertension
prevalence was not reported.
CKD prevalence was higher by the cystatin C equa-
tions compared with the creatinine-based equations in-
cluding CKD-EPIcr. A large proportion of participants
identified with CKD by the cystatin C-based equations
did not have CKD by the creatinine-based equations.
Cystatin C-based equations compared with creatinine-
based formulae have been suggested to more precisely
estimate GFR in black South Africans with early renal
disease [15]. Apart from GFR, cystatin C levels are not
affected by many factors that influence serum creatinine
such as muscle mass, diet, gender and age.
Additionally, the two cystatin C based equations were
fair-to-moderately correlated with the CKD-EPIcr,
MDRD and CGF. This suggests that the current
creatinine-based equations used to determine CKD in
the black South African population in clinical practice
may perhaps not be the best estimators if the cystatin C
equations are considered superior to the creatinine-
based formulae. The cystatin C equations have been re-
ported to show better precision and accuracy in deter-
mining GFR compared with CKD-EPIcr; however, this is
mainly in western populations [33].
Bukabau and colleagues report that in a study of 494
adults from two Sub-Saharan African countries equa-
tions with cystatin C alone or in combination with cre-
atinine did not improve GFR estimates or add
substantial value over CKD-EPIcr when compared with
measured GFR [16]. However, a Congolese study of 93
healthy adults found that CKD-EPIcys performed better
than CKD-EPIcr when compared with measured GFR
[34]. Nevertheless, the authors reported that slightly bet-
ter performance of the former equation was not enough
to warrant the additional costs of the cystatin C marker
in daily practice. The cost of performing the cystatin C
assay is high and there are delays in turnaround time be-
cause of the need for analyses to be conducted in
batches [15] making the frequent utilisation of this test
problematic. Therefore, concerns remain about the cost-
effectiveness and clinical significance of using cystatin
C-based eGFR estimators over creatinine-based formulae
in general populations [33]. It may therefore be prag-
matic to assess cystatin C if creatinine-based eGFR is
60–74mL/min per 1.73 m2 without albuminuria to ob-
tain a better estimate of GFR [12]. However, the 2013
Kidney Disease Improving Global Outcomes (KDIGO)
CKD Guideline Development Work Group suggests
measuring cystatin C for confirmation of CKD only
when markers of kidney damage are absent and eGFR by
creatinine-based formulae is 45–59 mL/min per 1.73 m2
[13]. Further research is necessary to establish guidelines
in the local population.
The differences in CKD prevalence estimates between
the creatinine and cystatin C based equations highlights
the need for South African population-based studies
with adequate sample sizes to validate these eGFR for-
mulae. This will provide the evidence needed to deter-
mine the appropriate eGFR equation to use in the local
setting. Further, if the latter is found to include cystatin
C, it may provide an impetus for improving cystatin C
assays and decreasing costs to enable widespread utility
of the test.
However, with regards to significant associations be-
tween CKD and cardiometabolic diseases, these were
best demonstrated with CKD-EPIcr followed by MDRD
in the adjusted models. There were no significant associ-
ations between any cardiometabolic parameter tested
and CKD determined by either cystatin C-based CKD
formulae when adjusted for age, gender and obesity.
This further underscore the need for in-depth research
on CKD in the local population.
The similar findings of significant associations in the
adjusted models for CKD-EPIcr and MDRD, as well as
their good correlations, is not surprising. This is because
both formulae are based on the same four variables al-
though the forms of the variables and the coefficients
differ. The strong agreement between CKD-EPIcr and
MDRD was also reported in the mixed ancestry South
African population [6].
The overall prevalence of CKD by a single threshold
value compared with age-specific thresholds was similar.
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However, the age-specific thresholds identified different
individuals with CKD compared with those identified
using a single threshold. The age-specific vs. the single
threshold cut-point identified a higher proportion of
younger participants < 40 years old (1.0–4.7% vs. 0.4–
1.4%, respectively) and a lower proportion of older par-
ticipants over 65 years of age (4.6–9.2% vs. 12.6–25.3%,
respectively). Therefore, the single threshold of 60 ml/
min per 1.73 m2 may overlook CKD in younger individ-
uals who do not display overt signs of kidney damage;
notably, mortality in individuals < 40 years of age has
been reported to increase at GFR < 75ml/min per 1.73
m2 [23]. Therefore, it is important to optimally identify
younger adults with early onset CKD to prevent progres-
sive kidney damage and adverse health outcomes.
In contrast, in > 65-year-old adults, the risk of mortal-
ity increases only at GFR < 45ml/min per 1.73 m2 [23].
Therefore, the threshold of 60 ml/min per 1.73 m2 may
over-diagnose CKD in the elderly; a large proportion of
older adults with eGFR between 45 and 59 ml/min per
1.73 m2 and no other signs of kidney damage should
perhaps not be classified as having CKD. Incorrect clas-
sification and diagnosis can lead to inappropriate care
and its associated adverse impacts such as unnecessary
healthcare expenditure and undue stress, among other
factors. Using age-specific CKD thresholds may improve
resource allocation with care directed to those at higher
risk of CKD associated adverse outcomes [23].The
higher prevalence of CKD in participants with compared
to without cardiometabolic disease risk factors, particu-
larly hypertension and diabetes, reflect their key roles in
renal damage. Reinforcing this, was that hypertension,
high heart rate, increasing LDL-C and metabolic syn-
drome were individually and separately related to CKD
by CKD-EPIcr and MDRD in the adjusted models while
diabetes was associated with CKD-EPIcr only. This high-
lights the need for regular screening of individuals with
cardiometabolic diseases to identify CKD as well as for
optimal management of hypertension and diabetes to
prevent renal and other complications [2].
Strengths and limitations
The strength of this study includes the large sample size
with a wide age range that included both sexes. Another
strength is the determination of eGFR using five equa-
tions including cystatin C. The findings of this study
may be generalised to urban black populations in other
South African cities with similar age demographics, car-
diometabolic patterns and other renal-related disorders.
A major limitation is the absence of measured GFR to
compare the estimated GFR values against; hence, eGFR
could not be validated against a gold standard. This
would have identified the eGFR equation that best corre-
lated with measured GFR and which could be use in this
population. It would have been ideal to repeat testing
after 3 months to confirm a diagnosis of CKD for accur-
ate prevalence rates; however, this was not possible and
is a drawback of this study. Neither was albuminuria nor
other markers of renal damage determined to more ac-
curately diagnose CKD. CKD classification includes the
presence of albuminuria even if eGFR is ≥60mL/min/
1.73 m2; therefore, we could have underestimated the
prevalence in this study. Our study could have been
underpowered to reliably estimate the prevalence of
CKD. A larger sample size may have been required to
estimate CKD prevalence (2–7%) compared with that re-
quired for an 8% diabetes prevalence. The cross-
sectional design of this study precluded conclusions on
causality between cardiometabolic diseases and CKD. A
further limitation, and a common characteristic of epi-
demiological studies in South Africa, is the low sample
realisation in men (64%), which may be related to their
unwillingness to participate, particularly for the drawing
of blood samples.
Conclusions
CVDs and other non-communicable diseases are draw-
ing increasing attention in South Africa; CKD, a key
non-communicable disease and CVD risk factor should
not be overlooked because of the potential public health
implications. Screening for CKD should be incorporated
into the routine assessment of high-risk patients such as
those with hypertension or diabetes. However, this study
highlights that CKD prevalence estimates can vary
within a population because of the different eGFR equa-
tions used. This underscores the need to improve the ac-
curacy of CKD diagnoses. Further research is needed in
the local setting to determine and validate the appropri-
ate measure to use when estimating renal function. On-
going CKD surveillance to monitor the burden is equally
important and should be considered in resource limited
settings like South Africa to pre-empt future escalations
in the CKD burden.
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